Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | -0.50% | |
50 DMA Support | Bullish | -0.50% | |
Multiple of Ten Bearish | Other | -0.50% | |
Bullish Engulfing | Bullish | -1.70% | |
Crossed Above 20 DMA | Bullish | -1.70% | |
Crossed Above 50 DMA | Bullish | -1.70% | |
MACD Bullish Centerline Cross | Bullish | -1.70% | |
180 Bullish Setup | Bullish Swing Setup | -1.70% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | -1.70% | |
Pocket Pivot | Bullish Swing Setup | -1.70% |
Alert | Time |
---|---|
Down 1% | 40 minutes ago |
20 DMA Support | about 1 hour ago |
50 DMA Support | about 1 hour ago |
Fell Below Previous Day's Low | about 1 hour ago |
Fell Below 20 DMA | about 1 hour ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Huntington's Disease Hemoglobin Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Hemoglobinopathies Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 218.88 |
52 Week Low | 141.975 |
Average Volume | 539,958 |
200-Day Moving Average | 169.05 |
50-Day Moving Average | 149.26 |
20-Day Moving Average | 148.60 |
10-Day Moving Average | 150.55 |
Average True Range | 4.26 |
RSI (14) | 49.75 |
ADX | 12.4 |
+DI | 15.95 |
-DI | 19.03 |
Chandelier Exit (Long, 3 ATRs) | 142.71 |
Chandelier Exit (Short, 3 ATRs) | 154.76 |
Upper Bollinger Bands | 155.03 |
Lower Bollinger Band | 142.17 |
Percent B (%b) | 0.56 |
BandWidth | 8.65 |
MACD Line | 0.08 |
MACD Signal Line | -0.05 |
MACD Histogram | 0.1345 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 154.68 | ||||
Resistance 3 (R3) | 154.91 | 153.37 | 153.80 | ||
Resistance 2 (R2) | 153.37 | 152.03 | 153.26 | 153.51 | |
Resistance 1 (R1) | 151.39 | 151.20 | 150.62 | 151.16 | 153.21 |
Pivot Point | 149.85 | 149.85 | 149.47 | 149.74 | 149.85 |
Support 1 (S1) | 147.87 | 148.51 | 147.10 | 147.64 | 145.59 |
Support 2 (S2) | 146.33 | 147.68 | 146.22 | 145.29 | |
Support 3 (S3) | 144.35 | 146.33 | 145.00 | ||
Support 4 (S4) | 144.12 |